Literature DB >> 26439085

Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus.

Ilhem Messaoudi1, Gaya K Amarasinghe2, Christopher F Basler3.   

Abstract

Ebola viruses and Marburg viruses, members of the filovirus family, are zoonotic pathogens that cause severe disease in people, as highlighted by the latest Ebola virus epidemic in West Africa. Filovirus disease is characterized by uncontrolled virus replication and the activation of host responses that contribute to pathogenesis. Underlying these phenomena is the potent suppression of host innate antiviral responses, particularly the type I interferon response, by viral proteins, which allows high levels of viral replication. In this Review, we describe the mechanisms used by filoviruses to block host innate immunity and discuss the links between immune evasion and filovirus pathogenesis.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26439085      PMCID： PMC5201123          DOI： 10.1038/nrmicro3524

Source DB:  PubMed          Journal:  Nat Rev Microbiol        ISSN： 1740-1526            Impact factor:   60.633


  160 in total

Review 1.  Dendritic cells: specialized and regulated antigen processing machines.

Authors:  I Mellman; R M Steinman
Journal:  Cell       Date:  2001-08-10       Impact factor: 41.582

2.  A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus.

Authors:  Amy L Hartman; Jonathan S Towner; Stuart T Nichol
Journal:  Virology       Date:  2004-10-25       Impact factor: 3.616

3.  The double-stranded RNA-binding protein PACT functions as a cellular activator of RIG-I to facilitate innate antiviral response.

Authors:  Kin-Hang Kok; Pak-Yin Lui; Ming-Him James Ng; Kam-Leung Siu; Shannon Wing Ngor Au; Dong-Yan Jin
Journal:  Cell Host Microbe       Date:  2011-04-21       Impact factor: 21.023

4.  Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal.

Authors:  Lisa A Lopez; Su Jung Yang; Heiko Hauser; Colin M Exline; Kevin G Haworth; Jill Oldenburg; Paula M Cannon
Journal:  J Virol       Date:  2010-05-05       Impact factor: 5.103

5.  Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection.

Authors:  Kartik Chandran; Nancy J Sullivan; Ute Felbor; Sean P Whelan; James M Cunningham
Journal:  Science       Date:  2005-04-14       Impact factor: 47.728

6.  Amino Acid Residue at Position 79 of Marburg Virus VP40 Confers Interferon Antagonism in Mouse Cells.

Authors:  Alicia R Feagins; Christopher F Basler
Journal:  J Infect Dis       Date:  2015-04-29       Impact factor: 5.226

7.  Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity.

Authors:  F J Neumann; I Ott; N Marx; T Luther; S Kenngott; M Gawaz; M Kotzsch; A Schömig
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-12       Impact factor: 8.311

8.  Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.

Authors:  Stuart J D Neil; Trinity Zang; Paul D Bieniasz
Journal:  Nature       Date:  2008-01-16       Impact factor: 49.962

9.  Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner.

Authors:  Asuka Nanbo; Masaki Imai; Shinji Watanabe; Takeshi Noda; Kei Takahashi; Gabriele Neumann; Peter Halfmann; Yoshihiro Kawaoka
Journal:  PLoS Pathog       Date:  2010-09-23       Impact factor: 6.823

10.  Structure of the Ebola VP35 interferon inhibitory domain.

Authors:  Daisy W Leung; Nathaniel D Ginder; D Bruce Fulton; Jay Nix; Christopher F Basler; Richard B Honzatko; Gaya K Amarasinghe
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-02       Impact factor: 11.205
View more
  89 in total

1.  A Sensitive in Vitro High-Throughput Screen To Identify Pan-filoviral Replication Inhibitors Targeting the VP35-NP Interface.

Authors:  Gai Liu; Peter J Nash; Britney Johnson; Colette Pietzsch; Ma Xenia G Ilagan; Alexander Bukreyev; Christopher F Basler; Terry L Bowlin; Donald T Moir; Daisy W Leung; Gaya K Amarasinghe
Journal:  ACS Infect Dis       Date:  2017-02-09       Impact factor: 5.084

2.  Structural Insight into Nucleoprotein Conformation Change Chaperoned by VP35 Peptide in Marburg Virus.

Authors:  Baocheng Liu; Shishang Dong; Guobang Li; Wenming Wang; Xiang Liu; Yantong Wang; Cheng Yang; Zihe Rao; Yu Guo
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

3.  Ebola Virus Inclusion Body Formation and RNA Synthesis Are Controlled by a Novel Domain of Nucleoprotein Interacting with VP35.

Authors:  Tsuyoshi Miyake; Charlotte M Farley; Benjamin E Neubauer; Thomas P Beddow; Thomas Hoenen; Daniel A Engel
Journal:  J Virol       Date:  2020-07-30       Impact factor: 5.103

4.  Ebola Virus Replication Stands Out.

Authors:  Wenjie Wang; Chao Wu; Gaya K Amarasinghe; Daisy W Leung
Journal:  Trends Microbiol       Date:  2019-05-30       Impact factor: 17.079

5.  A VP35 Mutant Ebola Virus Lacks Virulence but Can Elicit Protective Immunity to Wild-Type Virus Challenge.

Authors:  Courtney Woolsey; Andrea R Menicucci; Robert W Cross; Priya Luthra; Krystle N Agans; Viktoriya Borisevich; Joan B Geisbert; Chad E Mire; Karla A Fenton; Allen Jankeel; Sneha Anand; Hideki Ebihara; Thomas W Geisbert; Ilhem Messaoudi; Christopher F Basler
Journal:  Cell Rep       Date:  2019-09-17       Impact factor: 9.423

6.  VP24-Karyopherin Alpha Binding Affinities Differ between Ebolavirus Species, Influencing Interferon Inhibition and VP24 Stability.

Authors:  Toni M Schwarz; Megan R Edwards; Audrey Diederichs; Joshua B Alinger; Daisy W Leung; Gaya K Amarasinghe; Christopher F Basler
Journal:  J Virol       Date:  2017-01-31       Impact factor: 5.103

7.  Impact of Měnglà Virus Proteins on Human and Bat Innate Immune Pathways.

Authors:  Caroline G Williams; Joyce Sweeney Gibbons; Timothy R Keiffer; Priya Luthra; Megan R Edwards; Christopher F Basler
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

8.  Inhibiting pyrimidine biosynthesis impairs Ebola virus replication through depletion of nucleoside pools and activation of innate immune responses.

Authors:  Priya Luthra; Jacinth Naidoo; Colette A Pietzsch; Sampriti De; Sudip Khadka; Manu Anantpadma; Caroline G Williams; Megan R Edwards; Robert A Davey; Alexander Bukreyev; Joseph M Ready; Christopher F Basler
Journal:  Antiviral Res       Date:  2018-08-23       Impact factor: 5.970

9.  Role of Transmembrane Protein 16F in the Incorporation of Phosphatidylserine Into Budding Ebola Virus Virions.

Authors:  Patrick Younan; Mathieu Iampietro; Rodrigo I Santos; Palaniappan Ramanathan; Vsevolod L Popov; Alexander Bukreyev
Journal:  J Infect Dis       Date:  2018-11-22       Impact factor: 5.226

Review 10.  Post-exposure treatments for Ebola and Marburg virus infections.

Authors:  Robert W Cross; Chad E Mire; Heinz Feldmann; Thomas W Geisbert
Journal:  Nat Rev Drug Discov       Date:  2018-01-29       Impact factor: 84.694
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.